Abstract
Since its approval, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has improved lung function and decreased the number of pulmonary exacerbations in people with cystic fibrosis (pwCF). Here, we investigated the influence of ETI on the amount of oral and intravenous (iv) antibiotic therapies in pwCF since the initiation of ETI therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
